ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 21st World Congress on Gastrointestinal Cancer

 

3-6 July 2019 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  1-SO Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer. Shigenori Kadowaki Received Received
  1-PD Analysis of patient screening in the phase III, international, randomized, open-label APACT trial Michele Reni Received Received
  2-SO Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-nave advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF) Ian Chau Received Received
  3-LBA A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study) Yuko Hirano Received Received
  3-PD IDENTIFICATION OF A NANOSTRING SIGNATURE THAT DIFFERENTIATES EARLY PANCREATIC CANCERS ACCORDING TO STROMAL COMPOSITION AND PREDICTS CLINICAL OUTCOME Chiara Braconi Received Received
  3-P Perturbation of fatty acids of erythrocyte membranes and blood serum in patients with colorectal cancer: new opportunities for diagnostics Margarita Kruchinina Received Received
  4-P Nine years of epidemiological changes of gastrointestinal cancer in Egypt Rasha Aboelhassan Received Received
  4-PD Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC Umberto Peretti Received Received
  4-O Applied Precision Cancer Medicine in advanced Biliary Tract Cancer Hossein Taghizadeh Received Received
  5-P Increased FLVCR1 expression predicts poor prognosis and enhances malignant phenotypes in esophageal squamous cell carcinoma Suna Zhou Received Received
  6-P miR-381-3p inhibits migration and invasion in ESCC through downregulated FLVCR1 wenguang ye Received Received
  6-SO Hafnium oxide nanoparticles activated by SBRT: a new interventional radiation therapy approach for the treatment of unresectable liver cancers Omar Vivar Received Received
  7-O ZEBRA: An ACCRU/IRCI Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small Bowel Adenocarcinoma (SBA) Katrina Pedersen Received Received
  7-P Rectal cancer in Albania: treatment outcome and prognostic factors of disease progression. Elvisa Kozma Received Received
  8-LBA Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC Carlotta Antoniotti Received Received
  8-PD Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers Aparna Parikh Received Received
  9-P Prognostic factors of untreated hepatocellular carcinoma on cirrhosis STOIAN MARILENA Received Received
  10-P GLOMERULAR FILTRATION RATE TO LIVER TRANSPLANTATION STOIAN MARILENA Received Received
  10-O VOLTAGE: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer (EPOC 1504) Hideaki Bando Received Received
  12-PD Emerging risk factors of recurrence and overall survival in a Swedish stage I-III colon cancer cohort Erik Osterman Received Received
  12-P Weighted gene co-expression networks explored MiR-92b Implicated In esophageal squamous cell cancer Wanpeng Wang Received Received
  13-P Surgical and combined treatment for patients with cholangiocarcinoma: the experience of FSBI Aleksandr Polyakov Received Received
  13-PD RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC) Yu Sunakawa Received Received
  13-O Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies Gemma Zucchelli Received Received
  14-P Associations between primary cancer site, metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal cancer patients at end-of-life Shuji Hiramoto Received Received
  15-P Association between prognosis and discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received end-of-life chemotherapy Shuji Hiramoto Received Received
  15-PD Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies Daniele Rossini Received Received
  16-P Long-course chemoradiation in carcinoma rectum; is it really worth it? Perspectives from a developing nation DEEP CHAKRABARTI Received Received
  16-PD Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study Alessandra Raimondi Received Received
  17-O SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer Jun Watanabe Received Received
  18-P Prediction of oncologic outcome using systemic neutrophil-to-lymphocyte ratio in stage II and III colon cancer Youn Young Park Received Received
  19-P Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer lucheng Zhu Received Received
  20-PD Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC) Rahul Das Received Received
  20-O Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy Karen Gambaro Received Received
  20-P Surprisingly high prevalence of DPYD gene mutation in UK regional trust: implications for treatment Samantha Kestenbaum Received Received
  21-P Efficient treatment policies and its impact on the economic burden for CRC in low-middle income countries: the Egypt Case Abdalla Abotaleb Received Received
  22-PD PARP-ness in Metastatic Colorectal Cancer Gianluca Mauri Received Received
  22-O Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) Donna Stefanoni Received Received
  22-P Which patients on chemotherapy for colorectal cancer should be anticoagulated? Samantha Forner Received Received
  23-PD Survey on the Unmet Needs of Patients Living with mCRC Learnings from an International Study Zorana Maravic Received Received
  24-PD Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS Sarah Novack Received Received
  25-O A randomized, multicenter, phase II trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients filippo pietrantonio Received Received
  25-P Toxicity syndromes, patient-related clinical indicator of toxicity burden induced by intensive triplet chemotherapy-based regimens in metastatic gastrointestinal cancers Gemma Bruera Received Received
  27-P Multidirectional colonoscopy quality improvement increases adenoma detection rate: results of the Seoul national university hospital healthcare system Gangnam center colonoscopy quality upgrade project (Gangnam-CUP) Ji Yeon Seo Received Received
  27-PD Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis Daniele Rossini Received Received
  29-P Impact on survival of local complications in Pancreatic Cancer: experience at the Ramón y Cajal University Hospital (HURyC) Juan Jose Serrano Domingo Received Received
  30-P Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma Hongjie Chen Received Received
  31-PD Immune signatures identify three immune clusters in mCRC, with potential clinical implications Leire Pedrosa Received Received
  31-P Low level of centromere-associated protein E promotes growth of hepatocellular carcinoma and is associated with adverse clinical features Yiguang Lin Received Received
  32-P Hypofractionated volumetric modulated arc therapy (VMAT) in the treatment of advanced oesophageal cancer. Letizia Deantonio Received Received
  32-PD Comparison of surgical data and survival outcome of rectal cancer patients that need upfront surgery after chemoradiotherapy versus salvage surgery after watch-and-wait Philippe Bulens Received Received
  33-PD A prospective cohort study on the effect of radiotherapy for rectal cancer on female sexual function Annika Svanstrm Rjvall Received Received
  34-P PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer Alison Sinclair Received Received
  35-P Prognosis of gastric dysplasia according to mucin phenotype after complete resection with endoscopic procedures Jin-Oh Kim Received Received
  36-P Multidisciplinary approach associated with improved overall survival in metastatic colorectal cancer JOLANTA ZOK Received Received
  37-P Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities. Juan Luis Sanz Received Received
  39-P ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: results of a prospective single centre clinical utility study (PRECISE STUDY) Thomas Starkey Received Received
  40-P Cost of metastatic colorectal cancer drugs per month of life gained in Spain silvina grasso Received Received
  41-P Predictivity of body mass index, age and tumor laterality for systemic therapy outcome in metastatic colorectal cancer patients Amer Radwi Received Received
  43-P Scope position is a determining factor for diagnostic performance of EUS-FNA for mass lesions in the pancreas head and uncinate process Nam Hee Kim Received Received
  50-P The Velindre cancer centre experience of panitumumab versus cetuximab in combination with chemotherapy for metastatic colorectal cancer: a comparison of toxicity and economic evaluation. Amy Case Received Received
  51-P Predictors of response to 3rd line TAS-102 chemotherapy in metastatic colorectal cancer Vasileios Angelis Received Received
  53-P Neoadjuvant rectal cancer (NAR) score as a prognostic factor in locally advanced rectal cancer patients in Assiut university hospital clinical oncology department Mariam khalil Received Received
  54-P Retrospective analysis of the efficacy and safety of regorafenib in patients with advanced GIST Hiroshi Nakatsumi Received Received
  57-P Interleukin-6 correlated with neutrophil-to-lymphocyte ratio in pancreatic cancer Pop Vlad Vasile Received Received
  58-P Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis. Sarah Novack Received Received
  59-P SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC). Maria Loushin Received Received
  60-P Outcomes for 556 consecutive patients with stages I-III colon cancer managed in a single cancer center in Cyprus over 10 years Eleni Xenophontos Received Received
  62-P Predicting esophageal cancer outcome with positron emission tomography using deep convolutional neural network Po-Kuei Hsu Received Received
  63-P ROLE OF MAINTENANCE GEMCITABINE IN ADVANCED/METASTATIC CARCINOMA GALL BLADDER MANISH SHARMA Received Received
  64-P Self-expandable metal stent (SEMS) for esophageal-gastric junction versus pyloric area obstruction in advanced gastric cancer patients: a retrospective, comparative, single-center study Hee Seok Moon Received Received
  65-P A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study Junichi Nakazawa Received Received
  66-P Neutrophil/lymphocyte ratio in metastatic colorectal cancer: real-world data for evidence of its prognostic role Gonalo Nogueira-Costa Received Received
  69-P Acute pancreatitis after pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in an ongoing phase 1 study for peritoneal metastasis Guowei Kim Received Received
  70-P Esophageal cancer: 5 years of experience in a Mexican oncology reference center. Carlos Eduardo Salazar-Mejía Received Received
  72-P Effects of natural substances from Boswellia sacra and Nerium oleander (breastin) in colon and pancreatic cancer PANAGIOTIS PARSONIDIS Received Received
  73-P Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies Gerardo Rosati Received Received
  74-P A three-year study of epidemiological trends of gastrointestinal cancers in a Haitian cancer program Doukens Patrick Gilbert Received Received
  75-P SBRT in primary and metastatic liver disease: analysis after implementation in our center Carolina De la Pinta Received Received
  76-P Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features Chinock Cheong Received Received
  78-P Preoperative neutrophil to lymphocyte ratio as a prognostic factor for patients with colorectal cancer Ivica Zarev Received Received
  80-P Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase II trial (PRODIGE 58 UCGI 35 REGIRI) Laure Monard Received Received
  82-P Efficacy and safety of intermittent dosing schedule of apatinib for advanced gastric cancer in second-line setting Yifu He Received Received
  83-P FLOT- or CROSS-protocol treatment in advanced adenocarcinoma of the esophagus: a retrospective single-center analysis Jonas Herzberg Received Received
  85-P Rectal adenocarcinoma: clinical predictive factors for tumor response after chemoradiotherapy Carolina De la Pinta Received Received
  86-P EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment Merissa Lee Received Received
  88-P Radiology-guided oesophageal stenting for the palliation of dysphagia: a single center experience Rajarshi Roy Received Received
  89-P FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial Yara Torres Received Received
  92-P Impact on survival of adjuvant chemotherapy following chemo-radiotherapy and surgery in locally advanced, non-metastatic rectal adenocarcinoma: a retrospective analysis among 331 patients Marion SONDAG Received Received
  93-P Male gender and bone metastases linked to inferior survival in advanced biliary tract cancer Felipe Oliveira Received Received
  95-P Gastroenteropancreatic neuroendocrine neoplasia G3 according to 2017 WHO classification: a comprehensive clinicopathological characterization including mismatch repair proteins and PDL1 expression in a large cohort of patients Julieta Grasselli Received Received
  99-P Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients Emmanuelle SAMALIN Received Received
  100-P Trifluridine-tipiracil for the treatment of metastatic colorectal cancer patients: UK multicentre real-world experience Michael Tilby Received Received
  101-P A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy Alessandro Parisi Received Received
  102-P Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at a dose of 130mg/m2 (nacG-SOX130) in clinical(c)Stage III gastric cancer. Sayuri Konishi Received Received
  103-P Prognostic implications of free cancer cells in gastric juice in gastric cancer patients who underwent surgery: a prospective cohort study Dai Manaka Received Received
  104-P Potent anticolorectal cancer activity of 5-fluorouracil and laccaic acid combination via modulation of epigenetic regulation Riya Gupta Received Received
  108-P Quality of life assessment and reporting in colorectal cancer: a systematic review of phase III trials published between 2012 and 2018 Pasquale Lombardi Received Received
  112-P A retrospective study on treatment outcomes for patients with high grade neuroendocrine colorectal carcinoma. PAVLOS PISKILIDIS Received Received
  115-P The onset of grade = 3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil Jacopo Giuliani Received Received
  116-P GRADE evaluation of the COLOFOL randomized clinical trial Eduardo Ceballos Received Received
  117-P Stage IIa colon cancer: adjuvant chemotherapy in real life Renato Cunha Received Received
  123-P A Retrospective Qualitative Pilot Study Incorporating Patient Personal Life Aspects upon Admission to Palliative Care: What should we know about patients to give them the best care possible? Anna Kitta Received Received
  124-P Definitive chemoradiotherapy in oesophageal cancer: Treatment outcomes from a regional cancer centre Mohammed Abdul-Latif Received Received
  125-P Total neoadjuvant treatment of ugly rectal cancers in Slovenia Vaneja Velenik Received Received
  126-P The management of pancreatic adenocarcinoma in a hospitalized-based population (2015-2019) aicha bengueddach Received Received
  128-P Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease. Michele Ghidini Received Received
  129-P Expression of female sex hormone receptors, connective tissue growth factor, and HER2 in gallbladder cancer and adjacent normal tissue RENATA DUCHNOWSKA Received Received
  130-P Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study Mikhail Fedyanin Received Received
  132-P A novel LncRNA (LOC105371049) regulates colorectal cancer proliferation, metastasis and metabolism hongyan yu Received Received
  133-P A randomized, multicenter, open-label controlled phase II trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer Peter Morsing Received Received
  134-P Real-world guideline application in the management of pancreatic cancer patients: the Italian GARIBALDI study Michele Reni Received Received
  137-P Circulating T cell subsets differ in PDAC patients at initial diagnosis and after two months of treatment: a single institution prospective study Skaiste Tulyte Received Received
  138-P Alcohol consumption and tobacco smoking and ed gastrointestinal cancers morbidity rates in Poland Miroslaw Jarosz Received Received
  139-P Chemotherapy Rechallenge or Reintroduction (CTr/r), Regorafenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients: a PROpensity ScorE analysis of tReatment beyond the second liNe (PROSERpINa Study). Maria Alessandra Calegari Received Received
  140-P Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib VINCENZO RICCI Received Received
  142-P Sunitinib rechallenge in pancreatic neuroendocrine tumors Vasiliki Michalaki Received Received
  143-P Gastric cancer: system approach Oleg Kshivets Received Received
  144-P Impact of ileostomy in the adjuvant treatment of colorectal cancer stages II-III German Calderillo Received Received
  145-P Gastric cancer in young Latin women: bad prognostic factors and outcomes. German Calderillo Received Received
  147-P Surgery specialization as a prognostic factor in colon cancer German Calderillo Received Received
  150-P Perioperative FLOT experience: pathological regression and toxicity Adrián Sánchez Received Received
  154-P Correlation between neutrophil/lymphocyte ratio and postoperative infectious complications after pancreatoduodenectomy for carcinoma of the pancreas head Lucia Romano Received Received
  156-P Treatment for esophageal and esophagogastric junction cancer with radical radiotherapy: a single-institution cohort study Vesna Bisof Received Received
  157-P Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen. Nieves Martinez-Lago Received Received
  159-P Patterns and predictors of relapse following radical chemoradiotherapy delivered using intensity-modulated radiotherapy with a simultaneous integrated boost in anal squamous cell carcinoma. Rebecca Muirhead Received Received
  160-P Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours giulia arrivi Received Received
  162-P Dose-escalated intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost (SIB) in rectal cancer Rebecca Muirhead Received Received
  163-P Whole-exome sequencing of non-metastatic anal squamous cell carcinoma: a prognostic genetic variants analysis Ismael Ghanem Received Received
  166-P Systemic inflammatory response index (SIRI) predicts poor survival in pancreatic cancer patients treated with FOLFIRINOX Muhammad Bilal Razzaq Received Received
  168-P Maximum tolerated radiation dose for unresectable thoracic esophageal squamous cell carcinoma: both acute and late toxicities matter WEN YU Received Received
  170-P Nutritional index differential as a prognostic factor for recurrence in patients with locally advanced rectal cancer Ramos Maritza Received Received
  175-P The optimal time interval between self-expandable metallic stent placement and elective operation in patients with obstructive colon cancers: a multicenter retrospective analysis. BONG-HYEON KYE Received Received
  176-P Multicenter phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG1502) Tetsuhito Muranaka Received Received
  178-P A nomogram to predict poor health-related quality of life in metastatic colorectal cancer patients Vincenzo Formica Received Received
  179-P Retrospective analysis of 18 cases of gastric cancer with peritoneal metastases resulting in successful conversion surgery Rio Honma Received Received
  180-P A phase II study of capecitabine plus oxaliplatin therapy (XELOX) for patients with inoperable/advanced gastric cancer who were resistant/intolerable to fluoropyrimidine, CDDP, taxane, and CPT-11 (OGSG1403) Naotoshi Sugimoto Received Received
  181-P Efficacy of surgical resection in patients with recurrent tumor of intrahepatic cholangiocarcinoma Junichi Arita Received Received
  182-P Clinical importance of colonoscopy in patients with gastric cancer Hee chan Yang Received Received
  183-P Legumain is a predictive effector of peritoneal metastasis for diffuse gastric cancer patients Yan Wang Received Received
  184-P Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland Miroslaw Jarosz Received Received
  185-P Is intra-arterial hepatic chemotherapy painful? Fouad Kerbage Received Received
  186-P Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers Andrea Mafficini Received Received
  188-P Hepatic sinusoidal obstruction syndrome (HSOS) in cStage III gastric cancer patients undergoing neoadjuvant chemotherapy with oxaliplatin: a retrospective cohort study Kiyotaka Kawaguchi Received Received
  191-P Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND) Jorge Aparicio Received Received
  192-P Complete peritonectomy versus ive peritonectomy in peritoneal carcinomatosis secondary to colorectal cancer: a prospective comparative analysis of outcomes ASHWIN KR Received Received
  193-P FOLFIRINOX after first-line gemcitabine-based chemotherapy in metastatic pancreatic cancer: a mono-institutional experience FRANCESCA FOSCHINI Received Received
  194-P Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences SÍlvia Duarte Received Received
  195-P Coffee and alcohol consumption and trends in colorectal cancer morbidity in Poland Miroslaw Jarosz Received Received
  198-P Predictors of morbidity and mortality for patients with peritoneal carcinomatosis secondary to colorectal cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy ASHWIN KR Received Received
  199-P Role of robotic surgery for rectal cancer: short-term, functional, and oncological outcomes for 150 consecutive patients ASHWIN KR Received Received
  200-P Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer ASHWIN KR Received Received
  203-P The role of combined treatment of metastatic colorectal cancer in patients with liver metastases Danila Gridnev Received Received
  204-P Procalcitonin can be used to predict not only postoperative infectious complications but also prognosis in colorectal cancer Junghoon Bae Received Received
  205-P Hepatocellular carcinoma: characteristics, outcomes, and prognostic fators Adriana Novais Lopes Monteiro Soares Received Received
  206-P Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab Zoubida Behourah Received Received
  207-P Clinical and molecular characteristics of biliary tract carcinoma using next-generation sequencing Lucia Ceniceros Received Received
  208-P Phase II study in progress to verify improved response with mFOLFOX6 after exposure to an immune checkpoint inhibitor in advanced gastric cancer Ahn Ann Received Received
  209-P Sorafenib in patients with hepatocellular carcinoma: 10 years of real life Giulia Rovesti Received Received
  211-P A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel Cristina Morelli Received Received
  213-P CA19-9 decrease and predictive value for response in patients with metastatic pancreatic cancer treated with FOLFIRINOX José Francisco Rodríguez Hernández Received Received
  214-P Does PICC side matter? The experience at our hospital Ana Gil Torralvo Received Received
  215-P Recurrence rate in colorectal adenocarcinoma patients receiving adjuvant capecitabine monotherapy: do the number of chemotherapy cycles and relative dose intensity of the drug play a role? Joseph Sgouros Received Received
  216-P Neo-adjuvant Chemo-Radiation for Resectable Esophageal Carcinoma is Oral Capecitabine Non-Inferior to Paclitaxel Carboplatin Combination? ALOKE GHOSH DASTIDAR Received Received
  218-P L1CAM expression in colorectal cancer identifies patients prone to metastasis already in early-stage disease Athanasios Tampakis Received Received
  219-P Is there any affordable and reliable score in local gastric cancer? Antia Cousillas Received Received
  220-P Perioperative chemotherapy with FLOT vs other regimens for resectable gastric cancer Tamar Esakia Received Received
  221-P Locally advanced unresectable or metastatic pancreatic adenocarcinoma in patients under 65 years with good performance status (PS) at Ramón y Cajal University Hospital in Madrid Juan Jose Serrano Domingo Received Received
  223-P Quality of life and preoperative chemotherapy in gastric cancer in Chile: results from the observational study of perioperative chemotherapy in gastric cancer (PRECISO) Bettina Mller Received Received
  224-P HEPANOVA phase 2 study design: Tumor Treating Fields concomitant with sorafenib for the treatment of advanced hepatocellular carcinoma James Wallis Received Received
  226-P Efficacy of first-line systemic therapy for left-sided primary metastatic colon cancer - Single-centre retrospective cohort analysis of 186 patients Juraj Prejac Received Received
  227-P Real World Data (RWD) of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): clinical benefit from a Spanish single institution. Alberto Sánchez-Camacho Mejias Received Received
  228-P Tumor Treating Fields (150 kHz) combined with FOLFOX inhibits gastric cancer in vitro James Wallis Received Received
  229-P The value of alfa-fetoprotein and neutrophil/lymphocyte ratio (NLR) in the prognosis of patients with hepatocellular carcinoma Catarina Quintela Received Received
  230-P EFFECTIVENESS OF CA 19.9 IN PREDICTING PROGNOSIS IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH NAB-PACLITAXEL PLUS GEMCITABINE Stefano Mariani Received Received
  231-P Proinflammatory cytokines as predictive factors for response to chemotherapy or mental disorders present in colorectal cancer patients Pop Vlad Vasile Received Received
  232-P RENCA MACROBEAD THERAPY (RMB): A BIOLOGICAL-SYSTEMS APPROACH TO METASTATIC COLORECTAL CANCER U.S. FDA BB-IND 10091 Angelica Nazarian Received Received
  233-P Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma: a single center experience Ravi Paluri Received Received
  235-P Induction Chemotherapy with Taxane versus Anthracycline-based Triplet for Locally Unresectable Nonmetastatic Gastric Cancer Clara Borges Received Received
  236-P Histological Patterns and Clinical Characteristics of Metastatic Gastric Adenocarcinoma, Single institutional Experience in The Eastern Province of Saudi Arabia Nedal Bukhari Received Received
  237-P Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment? Tomislav Omrcen Received Received
  238-P Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy Donna Stefanoni Received Received
  239-P Sorafenib for advanced hepatocellular carcinoma (HCC) in the public health setting in Brazil: a cost-effectiveness analysis Rafael Carmo Received Received
  240-P Outcomes of Gastrointestinal cancers treated on Phase 1 clinical trials at ONeal Comprehensive Cancer Center Ravi Paluri Received Received
  243-P A comparison of the utilization and efficacy of palliative chemotherapy for the treatment of locally advanced or metastatic gastroesophageal carcinoma: a retrospective single-center analysis Aysegl Ilhan-Mutlu Received Received
  245-P Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancer Ravi Paluri Received Received
  246-P The importance of laterality in colorectal cancer predicting response to therapeutics retrospective study evaluating differences between right and left colon in stage IV colon cancer Élia Cipriano Received Received
  247-P SPLANCHNIC VEIN THROMBOSIS IN CHOLANGIOCARCINOMA. A RETROSPECTIVE OBSERVATIONAL STUDY. DONOSTIA UNIVERSITY HOSPITAL. ANA LANDA MAGDALENA Received Received
  248-P Futility and Utility of Two-stage Hepatectomy Miguel Cunha Received Received
  250-P The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and sorafenib shows in vitro and in vivo efficacy in hepatocellular carcinoma James Wallis Received Received
  251-P FLOT versus ECF/ECX peri-operative regimens in real life setting for patients with resectable gastric adenocarcinoma Joana Graa Received Received
  253-P Age vs Performance Status - Which is worst for surgery outcome? Edgar Amorim Received Received
  254-P LIQUID BIOPSY FOR RAS MUTATIONAL STATUS ANALYSIS IN METASTATIC COLORECTAL CANCER JOANA MARINHO Received Received
  255-P Outcomes of treatment for non-metastatic rectal cancer; a ten year single institute experience at the Bank of Cyprus Oncology Centre (BOCOC) Ifigenia Konstantinou Received Received
  256-P Locally advanced unresectable and metastatic pancreatic cancer predictors of survival Élia Cipriano Received Received
  258-P Computational simulations to determine the effectiveness and thermal safety of tumor treating fields with delivery to the abdomen James Wallis Received Received
  259-P A novel anti-tumorigenic mechanism by herbal extract saikosaponin-d through p-STAT3/C/EBP signaling suppression of COX-2 in liver cancer Yiguang Lin Received Received
  260-P PANOVA phase 3 study design: Tumor Treating Fields (150 kHz) in combination with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC) James Wallis Received Received
  262-P Percutaneous transhepatic biliary drainage in malignant biliary obstruction: complications and outcome MANOJ KUMAR Received Received
  264-P Chinese herbal medicine Sijunzi decoction alleviates liver cancer cachexia through downregulating TGF- and IGF 1 signaling pathways Yan Chen Received Received
  265-P RETROPERITONEAL LYMPH NODE METASTASES AS A PROGNOSIS FACTOR IN OVERALL SURVIVAL IN METASTATIC COLORECTAL CANCER German Calderillo Received Received
  266-P Metastatic pancreatic cancer: Characteristics of long-term survivors margaret mandelson Received Received
  267-P Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer Tatiana Titova Received Received
  268-P Association between primary perioperative CEA ratio, tumor site, and overall survival in patients with colorectal cancer Anup Kasi Received Received
  269-P PIPAC PACLITAXEL: A SYSTEMATIC AND PERITONEAL TISSUE PHARMACOKINETIC STUDY IN SWINE Hon Lyn Tan Received Received
  271-P Efficacy and tolerability of the combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experience Anup Kasi Received Received
  272-P Is the gastroenterologist really necessary in the operating room? Intraoperative rectosigmoidoscopy: how we do it. Edgar Amorim Received Received
  274-P A MULTICENTER SPANISH RETROSPECTIVE STUDY OF PLATINUM-BASED CHEMOTHERAPY SENSITIVITY IN THE FIRST LINE SETTING AFTER RELAPSE FROM PERIOPERATIVE PLATINUM BASED CHEMOTHERAPY IN GASTRIC CANCER Luis Paul Del Carpio Huerta Received Received
  275-P Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs) Massimiliano Salati Received Received
  277-P Socioeconomic and Administrative Factors Associated with Health&8209;care Delay and Treatment of Esophageal and Gastric Carcinoma: Experience at a Tertiary Care Centre in a Developing Country SYED ADIL HASSAN Received Received
  281-P EFFICACY OF A THERAPEUTIC EXERCISE PROGRAM ON AUTONOMIC NERVOUS SYSTEM FUNCTION, CARDIAC FUNCTION AND FUNCTIONAL CAPACITY IN COLORECTAL CANCER SURVIVORS: A RANDOMIZED CONTROLLED PILOT STUDY Julia Ruiz-Vozmediano Received Received
  283-P Predictors of Oxaliplatin-Induced Hepatotoxicity: Increase in Spleen Volume or Liver Fibrosis and Steatosis? Malek Kreidieh Received Received
  285-P The role of active nutritional intervention in patients receiving chemoradiation (CRT) for oesophageal cancer Rob Owens Received Received
  286-P The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with FIRST-LINE NAB-PACLITAXEL AND GEMCITABINE: POST-HOC ANALYSIS OF an Austrian multicenter, non-interventional study Jakob M. Riedl Received Received
  288-P The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) Debora Basile Received Received
  289-P Incidence and severity of cancer-related fatigue in gastric cancer patients Bogdan Gafton Received Received
  290-P Comparative analyses between younger and older patients with pancreatic adenocarcinoma: differences in clinicopathological features, treatment patterns, and outcomes Kunal Kadakia Received Received
  291-P NRG1-fusion positive gastrointestinal tumours: Afatinib as a novel potential treatment option Benjamin Weinberg Received Received
  293-P EVALUATION OF NEOANGIOGENESIS IN LOCALLY ADVANCED GASTRIC CANCER BEFORE AND AFTER NEOADJUVANT RADIOCHEMOTHERAPY BY PROBE CONFOCAL LASER ENDOMICROSCOPY (PCLE) Renato Cannizzaro Received Received
  294-P Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis Lisa Salvatore Received Received
  296-P Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience Andrea Pretta Received Received
  297-P Serum level of miRNA-143 as a potential prognostic marker in patients with colorectal cancer and synchronous metastatic disease Maria Radanova Received Received
  298-P Directed differentiation of human pluripotent stem cells into hepatic tissue with gallbladder and bile ducts organoids in vitro Fenfang Wu Received Received
  300-P Pancreatic Cancer resection in elderly patients: Analysis of outcomes MARIANA GARCÍA VIROSTA Received Received
  302-P Prospective Evaluation of FOLFIRINOX in Neo-adjuvant Treatment of Gastro-Oesophageal Junction Carcinomas Nicholas Travers Received Received
  303-P Third-line re-treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel Adarsh Das Received Received
  304-P Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less Adarsh Das Received Received
  305-P K-Ras mutation in liquid biopsy and tumor tissue correlation in patients with pancreatic cancer EDUARDO JOSÉ PERDOMO ZALDIVAR Received Received
  306-P Anal cancer outcomes and human immunodeficiency virus: a single-center experience Carmen García Durán Received Received
  307-P Epidemiology, treatment and prognostic factors of colorectal cancers in Tunisia: compliance with recommendations and therapeutic results Sarra Karrit Received Received
  308-P Role of TILS in predicting evolution of metastatic colorectal cancer sonia ben nasr Received Received
  310-P Efficacy of FOLFIRI as a second-line in extrapulmonary poorly-differentiated neuroendocrine carcinoma Carles Fabregat Franco Received Received
  314-P Do we need adjuvant therapy in patients with rectal cancer and pathologic complete response, after conventional preoperative chemoradiation and laparoscopic (LapTME) or Transanal total mesorectal excision (TaTME)? ROXANA REYES Received Received
  315-P ?Np73 and ?133p53 in liquid biopsy as early diagnostic markers for colorectal cancer Javier Rodríguez-Cobos Received Received
  316-P Outcomes of gastrointestinal tumours in the tyrosine kinase inhibitor era: 15 years of experience from a single tertiary care centre in India. Prabhat Bhargava Received Received
  317-P Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study) Maria Bensi Received Received
  319-P Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer Lorenzo Fornaro Received Received
  320-P Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: real-world data of 13 oncological centers in Portugal Tiago Cruz Tomás Received Received
  321-P Young Onset Rectal Cancer: a Therapeutic Challenge Debapriya Mondal Received Received
  323-P Is FNA always necessary in submucosal lesion miming GIST? Renato Cannizzaro Received Received
  324-P Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Experience Rojymon Jacob Received Received
  326-P CLINICAL PRACTICE USE OF LIQUID BIOPSY TO IDENTIFY RAS/BRAF MUTATIONAL STATUS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): A SINGLE INSTITUTION EXPERIENCE Vincenzo De Falco Received Received
  328-P Treatment of Metastatic Colorectal Cancer in the Real World (mCRC): Final Results from a European Survey Zorana Maravic Received Received
  330-P Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data Pasquale Vitale Received Received
  331-P Paclitaxel plus ramucirumab combination therapy as second-line therapy in elderly patients with metastatic advanced gastric cancer: A single-center retrospective study. Tomomi Kashiwada Received Received
  332-P A new prognostic score for biliary tract cancer: a multicenter experience Pina Ziranu Received Received
  333-P Early fluorescence detection of oropharengeal and esophageal cancer Rasul Sadykov Received Received
  335-P FOLFIRINOX versus Nab-paclitaxel plus gemcitabine in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: a multivariate analysis of prognostic factors in a national cohort (Comunica-TTD working group). Federico Longo Muñoz Received Received
  339-P Epidemiology, treatment modalities and prognostic factors of colon cancer in the central region of Tunisia Imtinen Belaid Received Received
  341-P Health disparities and gastric cancer survival in Cali, Colombia: a hospital-based study Angela Zambrano Received Received
  344-P Survival analysis of gastric cancer in a Hispanic population: 15-years of experience at a specialized cancer center Angela Zambrano Received Received
  346-P A single center experience with oral chemotherapy with capecitabine and temozolomide in metastatic neuroendocrine tumors Ines Rego Received Received
  347-P THE RISK OF HEPATITIS B VIRUS (HBV) REACTIVATION IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) UNDER IMATINIB MESYLATE TREATMENT DIMITRIOS TZILVES Received Received
  348-P Esophageal cancer: about 42 cases Experience of the medical oncology department of Hassan II University Hospital of Fez, Morocco Nouiakh Lamyae Received Received
  350-P Management of gallbladder cancer - EXPERIENCE OF MEDICAL ONCOLOGY DEPARTMENT ABOUT 140 CASES Nouiakh Lamyae Received Received
  352-P Prognostic Value, Clinicopathologic Features and Diagnostic Accuracy of Interleukin-8 in Colorectal Cancer: A prospective study in 60 patients in Tunisia. Sarra Karrit Received Received
  354-P Survival and prognostic factors of localized gastric carcinomas (about 50 cases). Experience of the medical oncology department of Hassan II University of Fez hayat erraichi Received Received
  355-P To investigate the role of PGD2 and its receptor signalling in colon cancer pathophysiology Pujarini Dash Received Received
  356-P COLORECTAL CANCER IN YOUNG TUNISIAN PATIENTS: clinical, histopathological and RAS testing data HAYFA GUETTITI TOUNSI Received Received
  362-P Reasons for chemotherapy discontinuation and end of life in gastro-intestinal cancers: a multicentric prospective AGEO study Solene Doat Received Received
  364-P High expression of oestrogen receptor beta correlates with anti-tumorigenic inflammatory proteins in colorectal cancer. Geriolda Topi Received Received
  366-P Diagnostic and prognostic value of P53 and the human Programmed cell death 4 (PDCD-4) genes in colorectal cancer Enas Elkhouly Received Received
  367-P Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in malignant peritoneal disease: a review on outcomes for colorectal cancer Joana Simes Received Received
  368-P Chemoradiation and surgery versus chemoradiation followed by neoadjuvant chemotherapy and surgery in locally advanced rectal cancer: a retrospective analysis of a single center experience Bárbara Lima Received Received
  369-P Home chemotherapy in colorectal cancer: First experience in Argentina guillermo streich Received Received
  370-P Role of radiotherapy in local control of metastatic rectal cancer: a single-center experience Ana Afonso Received Received
  371-P Feasibility of modulated electro-hyperthermia as a concomitant boost to preoperative radiotherapy in locally advanced rectal cancer: A phase 2 trial Seihwan You Received Received
  375-P Palliative management of malignant biliary obstruction in patients with advanced biliary tract cancers SOUMIA berrad Received Received
  376-P Primary malignant tumors of the small intestine: clinical and therapeutic aspects SOUMIA berrad Received Received
  381-P The management of neuroendocrine gastroenteropancreatic tumors. SOUMIA berrad Received Received
  383-P Survival and prognostic factors for stage II colon cancer SOUMIA berrad Received Received
  384-P Anal Carcinoma A comparative analysis of the standard treatment vs An hypofractionated schedule (the Tlalpan Regime) experience at the Instituto Nacional de Cancerología, México. Jesús Zamora Received Received
  385-P PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib Long Pan Received Received
  389-P Clinical Significance of BRAF Mutations in Colorectal Cancer: A Retrospective Study of One Institution in a real-life population. Lidia Carnerero Córdoba Received Received
  392-P Minimally invasive surgical approach for the treatment of esophageal cancer as a component of multimodal treatment Yestay Abzalbek Received Received
  395-P Expression of MMR in Women High Grade Carcinoma of Unknown Primary Joni Howells Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30, Fri 8:30-15:00
00:25
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 21st World Congress on Gastrointestinal Cancer

 

3-6 July 2019 Barcelona
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 03/07/2019 TO 03/07/2020
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.21wcgic.2019 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 30/06/2019
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster




PosterSessionOnline
Logo Draft
 
Logo Cert